The newsroom features top highlights of Mayo Clinic Laboratories and its experts in the news. For media inquiries and expert interviews, contact the Media Relations Newsroom at firstname.lastname@example.org, attention: Mayo Clinic Laboratories.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, discuss why avian influenza has recently been in the news and lessons learned from managing COVID-19.
Since March 2020, the COVID-19 pandemic has had a lasting impact on the lives of millions of people around the world, including the many brave health care workers who risked their own health to provide lifesaving care to those infected by the virus. That care was made possible, in part, by the lasting impact that the pandemic has also had on laboratory testing.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with podcast host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss advances in monkeypox testing, working with the CDC to scale testing and response efforts, the fast-spreading BA.5 variant of COVID-19, and how at-home testing affects the number of reported cases.
Diagnostic tests are a critical part of America’s health infrastructure and helping people live healthier lives. But in a recent op-ed published on RealClearPolicy, William Morice II, M.D., president of Mayo Clinic Laboratories and Matt Sause, president and CEO of Roche Diagnostics North America, explain how the well-intended Protecting Access to Medicare Act of 2014 (PAMA) puts vital diagnostic tests at risk.
Mayo Clinic Laboratories' rapid response to public health threats has been honed during outbreaks of viruses like 2009’s H1N1 influenza, Zika, Ebola and, most recently, COVID-19. Before COVID-19, laboratory staff were already experts in developing and implementing new tests — but never on such an aggressive timeline.